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Abstract
GlycoPep Grader (GPG) is a freely-available software tool designed to accelerate the process of
accurately determining glycopeptide composition from tandem mass spectrometric data. GPG
relies on the identification of unique dissociation patterns shown for high mannose, hybrid, and
complex N-linked glycoprotein types, including patterns specific to those structures containing
fucose or sialic acid residues. The novel GPG scoring algorithm scores potential candidate
compositions of the same nominal mass against MS/MS data through evaluation of the Y1 ion and
other peptide-containing product ions, across multiple charge states, when applicable. In addition
to evaluating the peptide portions of a given glycopeptide, the GPG algorithm predicts and scores
product ions that result from unique neutral losses of terminal glycans. GPG has been applied to a
variety of glycoproteins, including RNase B, asialofetuin and transferrin, and the HIV envelope
glycoprotein, CON-S gp140 CFI. The GPG software is implemented predominantly in
PostgreSQL, with PHP as the presentation tier, and is publically accessible online. Thus far, the
algorithm has identified the correct compositional assignment from multiple candidate N-
glycopeptides in all tests performed.
INTRODUCTION
Among all co/post-translational modifications, glycosylation is widely regarded as both the
most frequent and most complex that proteins undertake. 1, 2, 3, 4 It is well-documented that
glycosylation regulates a variety of intra- and extra-cellular processes. 3, 4, 5, 6, 7, 8, 9
Cellular communication and transport events, 5, 6 and mechanisms of protein folding,3, 5, 6
degradation, 3, 5 and enzymatic interaction, 7 have all been shown to be regulated by
glycosylation, the majority of which are N-linked in type. 1 As such, the availability of mass
spectrometry (MS) tools to speed the identification of glycosylation profiles is critical to the
elucidation of their physiological importance. 3, 8, 10, 11, 12
Typically, glycosylation analysis using mass spectrometry (MS) techniques is accomplished
using one of two approaches: Glycan analysis and glycopeptide analysis. 12 The most
information-rich of these methods is glycopeptide analysis, as glycosylation characteristics
at individual sites of glycan attachment are readily identifiable. 2, 12 High resolution MS
data is used to determine potential candidate compositions for mass spectral peaks that are
suspected or known to be from glycopeptides. Computer-based programs such as
Glycomod 13 and GlycoPep DB 14 calculate glycopeptide candidate compositions on the
basis of mass information, as do a number of custom-generated databases. 15, 16
Unfortunately, a large amount of mass redundancy is typically encountered in glycopeptide
analysis. Many different combinations of glycan composition + peptide composition are
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isobaric, 15 so multiple candidate compositions frequently correspond to the same nominal
mass. Therefore, while high resolution MS data is useful for predicting possible
glycopeptide candidate compositions, it alone is not sufficient to identify glycopeptides
unambiguously. As a result, MS/MS experiments are often necessary to correctly assign
glycopeptide compositions. When the analyses of these data are performed manually, the
process is laborious, time-consuming, and requires significant expertise. 3, 4, 17
A few unique strategies have been developed to automate the process of scoring MS/MS
data against potential glycopeptide compositions. These include programs described in
references 18, 19, 20, 21, 22. However, none of these analysis tools are freely-accessible to
the public. 18, 19, 20, 21, 22.In terms of those tools that are publically available for
glycopeptide analysis, many have been designed to predominantly analyze the fragmentation
of glycans.23, 24 Although these tools are capable of analyzing glycopeptides, the peptide
component must be known in advance, which severely limits their utility for analysis of
unknown glycopeptides. 23, 24 GlycoWorkBench, 23 and Glyco-Peakfinder 24 both utilize
this approach for the annotation of glycans in glycopeptide data. A completely different
approach is utilized by GlycoPep ID, a web-based tool developed by Go et al. 25 GlycoPep
ID interprets MS/MS data of glycopeptides to identify the peptide component of
glycopeptides through analysis of expected product ions, but the key disadvantage of this
program is that it does not include a scoring function. 25
The most promising publically-accessible tool specifically designed to interpret and score
MS/MS data of glycopeptides is GlycoMiner, developed by Ozohanics et al. 26 This
program was designed to analyze qTOF data, and is capable of identifying and assigning
glycopeptide compositions when both the peptide and glycan portions are unknown.
Although this program is a great advancement in the automation of glycopeptide MS/MS
analysis, GlycoMiner often generates multiple plausible compositions and fails to rank the
correct glycopeptide as the top candidate, instead listing it as one of the most probable
compositions. 26 In addition, the program requires the presence of low-mass marker ions,
which are generally not present in data collected on ion trap instruments. The program also
requires the MS/MS data to be transformed into singly charged ions, prior to analysis. This
transformation is often not possible when analyzing low-resolution MS/MS data, such as
that from an ion trap mass spectrometer. Finally, GlycoMiner requires MS/MS data
containing a low S/N ratio. 26
GlycoPep Grader, which aims to expedite the characterization of N-linked glycopeptides by
evaluating both the glycan and peptide portions through a series of devised fragmentation
rules, was developed in an effort to overcome the limitations of the currently available tools.
The novel algorithm calculates and scores any given glycopeptide candidate composition by
searching MS/MS data for two types of product ions: 1) Those containing the peptide
portion, [peptide + core component] ions, and 2) Those resulting from neutral losses of
terminal monosaccharides, [precursor – monosaccharide] ions. The use of GlycoPep Grader
in determining glycopeptide compositions is not contingent upon any spectral requirements,
such the presence of specific marker ions. In addition, the GPG algorithm analyzes MS/MS
data in a charge-state dependent fashion, bypassing the need for transformation of spectra to
singly-charged ions. These features have resulted in a highly accurate automated analysis
tool that deciphers glycopeptide compositions. GPG is freely-available online; it can be
accessed at http://glycopro.chem.ku.edu/GPGHome.php.
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Details regarding the materials and reagents, along with the experimental protocols for
sample preparation and MS analysis of glycopeptides can be found in the Supplemental
Materials.
Development of a Gycopeptide Training Set
In order to develop the GPG algorithm, a set of “known” glycopeptides and their MS/MS
data were required; the training set included glycopeptides from RNase B, asialofetuin and
transferrin, as these are well characterized samples. 27, 28, 29 To identify the glycopeptides
from these samples in the MS data, a prediction table of theoretical m/z values
corresponding to glycopeptide compositions for each of the three proteins was prepared. The
amino acid sequences from RNase B, asialofetuin, and transferrin were obtained from
Uniprot (www.uniprot.org) and their sequences were imported into Protein Prospector
(http://prospector.ucsf.edu/prospector/mshome.htm) where tryptic peptides containing Cys
residues were modified with carbamidomethylation, and a theoretical tryptic digest was
performed to consider up to two tryptic miscleavages. The masses of the peptides that
contained potential N-linked glycosylation sites were added to the masses of the known
glycan compositions for each glycosylation site, in order to obtain glycopeptide masses.
These masses were converted into m/z values corresponding to the glycopeptides in multiple
charge states. The MS/MS data for RNase B, asialofetuin, and transferrin were then
searched to identify spectra that corresponded to the correct m/z value for a given
glycopeptide composition. The MS/MS data were carefully (manually) evaluated, to verify
the glycopeptide assignment.
The Glycopeptide Validation Set—In order to test the GPG software, a validation set of
glycopeptide compositions that were not used in the fragmentation studies or algorithm
development was necessary. The validation set for these studies comprised data from a
glycoprotein, CON-S gp140 CFI, which had been previously analyzed in our laboratory. 30
Data from this protein was selected because prior analyses demonstrated that all the
necessary glycoform types were present as glycopeptides (including high mannose and
complex/hybrid structures with and without sialic acid and fucose.) Additionally, since the
protein has more than 25 glycosylation sites, a wide variety of glycosylated peptide
sequences were also available. Furthermore, all the MS/MS data on this protein had been
previously analyzed manually, as described elsewhere. 30
Software Platform: GlycoPep Grader is a Web service implementation of our algorithm,
encapsulating data submission and analysis as a computational session. This transaction-
processing approach protects our Web service against the thankless perils that come with
providing anonymous data acceptance and computational services on the Internet, while
simultaneously ensuring the correctness of the computation. The graphical user interface
(GUI) code is built to conform with ECMAScript and W3C DOM standards, and we chose
the open-source, globally-distributed Mozilla Firefox Web browser as the reference platform
for the GUI presentation. The computational engine is implemented on common Web server
and database software, with a variety of implementation-specific optimizations for
computationally-intensive hotspots in the algorithm. These optimizations include deep logic
reordering, pre-calculations of elicited constants, and pre-compilations of common loops.
Finally, we use AJAX technology (Asynchronous Javascript And XML) to achieve state
continuity and provide a responsive, interactive experience to the user.
Prior to using GlycoPep Grader, the user must first successfully complete a simple math
problem embedded in a CAPTCHA (completely automated public Turing test to tell
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computers and humans apart). This security step helps prevent automated abuse of the Web
server. GlycoPep Grader then accepts user input, including candidate glycopeptide
compositions, the m/z and charge state of the precursor ion, and MS/MS data (which the
user provides in a .CSV file). The Web service performs server-side validation of the
submitted data for type, format, size, and range correctness. Once the data obtains
correctness approval, the computational engine performs its analysis of the glycopeptide
candidates against the spectral data. When the analysis is complete, the computational
engine assembles and returns the results to the GUI code listening on the user’s Firefox Web
browser.
Generation and Input of Glycopeptide Candidate Compositions—After the MS/
MS peak list file (along with the corresponding charge state and m/z of the precursor ion) is
uploaded to GPG in .CSV file format, peptide compositions are input manually by listing the
amino acid sequence of each glycopeptide candidate ion vertically on a separate line. The
glycopeptide candidate compositions are obtained by the user through freely-accessible
programs such as GlycoMod 13 or GlycoPep DB14, or custom-generated databases.15-16 The
GPG analysis tool then quickly calculates and searches for the [peptide + core component]
product ions that it predicts to be present for each of the peptide portions entered. In the next
window, the glycan portions for each of the candidate glycopeptides are manually entered in
the same order using the following format, where n = the number of each monosaccharide
residue and Neu5Ac = sialic acid: [HexNAc]n[Hex]n[Neu5Ac]n[Fuc]n. After GPG
evaluates the uploaded MS/MS peak list for product ions expected to be present for each
glycan, a final score is displayed in the output for each of the user-entered glycopeptide
compositions.
Generation and Input of Glycopeptide Candidate Compositions
After the MS/MS peak list file (along with the corresponding charge state and m/z of the
precursor ion) is uploaded to GPG in .CSV file format, peptide compositions are input
manually by listing the amino acid sequence of each glycopeptide candidate ion vertically
on a separate line. The glycopeptide candidate compositions are obtained by the user
through freely-accessible programs such as GlycoMod 13 or GlycoPep DB 14, or custom-
generated databases.15-16 The GPG analysis tool then quickly calculates and searches for the
[peptide + core component] product ions that it predicts to be present for each of the peptide
portions entered. In the next window, the glycan portions for each of the candidate
glycopeptides are manually entered in the same order using the following format, where n =
the number of each monosaccharide residue and Neu5Ac = sialic acid:
[HexNAc]n[Hex]n[Neu5Ac]n[Fuc]n. After GPG evaluates the uploaded MS/MS peak list
for product ions expected to be present for each glycan, a final score is displayed in the
output for each of the user-entered glycopeptide compositions.
Determination of False Discovery Rates and Scoring of Candidate Compositions
Decoy candidate compositions for all data sets were generated using an in-house database
where a decoy polypeptide of 50,000 amino acid residues, Titin, was multiplexed to a
biologically relevant library of approximately 200 glycans. (These glycans are the same ones
used in the on-online tool, GlycoPep DB.14) All selected decoy candidate compositions have
a calculated neutral mass that is within 50 ppm of the FT-ICR MS monoisotopic peak value
of the glycopeptide precursor ion for the CID spectrum tested. The decoy glycopeptide
compositions, along with the correct glycopeptide composition assignment, were used to
determine the false discovery rate of the GPG tool.
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GlycoPep Grader (GPG) was designed to analyze N-linked glycopeptides’ CID data. RNase
B, asialofetuin, and transferrin were chosen as model glycoproteins for the initial
development of the GPG algorithm because they are well characterized and contain various
glycoform types. Detailed information on the glycosylation characteristics of glycopeptides
used for the development and validation of the GPG algorithm and analysis tool is included
in supplementary material (Supplementary Table 1).
CID Studies and N-Glycopeptide Fragmentation Rules
Representative data from glycopeptides of RNase B, asialofetuin, and transferrin, are shown
in Figure 1. These data show typical fragmentation patterns for glycopeptides in the
following categories: A) high mannose type, B) complex or hybrid type and C) complex
type structures containing the more labile residues of sialic acid and/or fucose. The CID
spectra of these glycopeptides illustrate that many of the same types of product ions were
detected in the glycopeptide MS/MS data, regardless of the attached glycan composition.
Specifically, product ions containing the peptide and portions of the pentasaccharide core
were found in all these spectra and most other spectra in the training set, regardless of the
glycan type. Herein, those peptide-containing product ions are referred to as the [peptide +
core component] ions. The GlycoPep Grader algorithm uses the presence of these ions to
score the peptide portion of the candidate glycopeptide composition, included in
Supplementary Materials. The Y1 ion, which contains the peptide and one HexNAc residue
from the pentasaccharide core, has been shown to be a highly abundant ion in MS/MS data
collected on glycopeptides. This product ion is also considered a very indicative identifier of
a glycopeptide’s peptide portion,31 so the GPG algorithm weights this ion more heavily and
scores it on the basis of its intensity as well.
From the MS/MS data we obtained, the [peptide + core component] product ions were found
to be present in multiple charge states, when the charge state of the precursor ion was greater
than one, as shown in Figure 1. For all three model glycopeptides, these product ions were
detected in both the precursor’s charge state and the next lowest charge states, as shown by
the left panel in Figure 1A-C. This finding is consistent with previous reports by Lebrilla
and coworkers. 32 Therefore, the GPG algorithm scores these ions across multiple charge
states. In detail, if a CID spectrum was acquired on a glycopeptide precursor ion in the 4+
charge state, the GPG software would search for m/z values corresponding to the [peptide +
core component] product ions for the 4+, 3+, 2+, and 1+ charge state, as long as their
calculated values fall within the scan range.
The second predominant type of product ion detected in the glycopeptide training set data
were neutral losses of terminal monosaccharides from the glycopeptide precursor ion. In
contrast to the [peptide + core component] fragmentation, neutral losses from the precursor
ion observed for the three model glycoprotein types were unique to each candidate’s
carbohydrate composition. These ions, herein referred to as the [precursor –
monosaccharide] product ions, are used to score the glycan portion of the candidate
glycopeptide’s composition.
An example highlighting the glycan-specific fragmentation for glycopeptides is shown in
Figure 1. In the right panel of Figure 1A data for a high mannose type glycopeptide show
sequential mannose losses, and the neutral loss of this residue as the predominant
fragmentation for high mannose containing glycopeptides is well established. 28, 33, 34 These
ions are typically present in the spectrum in the same charge state as the precursor ion.
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For complex or hybrid bi- and tri-antennary structures containing no labile fucose or sialic
residues, (such as the representative glycopeptide in the right panel of Figure 1B), the
predominant neutral losses were found to be dependent on the total number of HexNAc vs.
Hex monosaccharide residues. If there are more HexNAc residues than Hex residues, the
key diagnostic loss most commonly observed in the training set was shown to be loss of two
HexNAc from the glycopeptide precursor ion. In comparison, those compositions containing
more Hex residues than HexNAc residues showed a key diagnostic loss corresponding to the
loss of [Hex + HexNAc] from the precursor ion. Figure 1B shows an example where the
[Hex + HexNAc] loss is readily detected. The GPG algorithm scores these ions to verify the
glycan portion of the glycopeptides.
Finally, for CID spectra collected on glycopeptides containing labile residues such as sialic
acid or fucose, the predominant [precursor – monosaccharide] product ion is the neutral loss
of these labile residues from the glycopeptide precursor. For example, in the right panel of
Figure 1C, loss of sialic acid is detectable as a major product ion. Often, these ions are
detected in both the precursor ion’s charge state, and in the charge state below that of the
precursor ion. (While data for only a glycopeptide containing sialic acid is shown,
glycopeptides containing at least one fucose residue generally follow the same trend, since
fucose is also a more labile monosaccharide.)
Although other neutral losses corresponding to the [precursor – monosaccharide] product
ion types are often present in CID spectra collected on the glycopeptides, (these ions are in
gray in the figure) the ions were not shown to be unique enough to discriminate among
various potential glycan substituent compositions. Therefore, these neutral losses were not
scored.
Novel GPG Scoring Algorithm
Figure 2 summarizes a simplified version of the scoring scheme used in GPG. A more
detailed version of the scoring system, as it stands currently, is available at
http://glycopro.chem.ku.edu/GPGHome.php. The original scoring algorithm is also available
in the Supplementary Material. For scoring the peptide portion, the [peptide + core
component] product ions are calculated for the candidate glycopeptide beginning with the
[naked peptide] and continuing through the [peptide + intact pentasaccharide core] for a total
six possible [peptide + core component] product ions: 1. [naked peptide], 2. [peptide +
HexNAc], 3. [peptide + 2HexNAc], 4. [peptide + 2HexNAc + Hex], 5. [peptide + 2HexNAc
+ 2Hex], and 6. [peptide + 2HexNAc + 3Hex]. Each of these ions is then searched for in the
MS/MS data in multiple charge states, as explained above. The scoring algorithm for these
ions does not change, regardless of the N-linked glycopeptide type.
Separate fragmentation rules are implemented for the glycan portion of the glycopeptide,
depending on which types of glycans are present in the candidate composition. To determine
which fragmentation rules apply, the glycan is first evaluated against eight possible
categories including: 1) high mannose type glycans without appended fucose; 2) high
mannose glycans that also contain fucose; 3) complex or hybrid structures containing sialic
acid (defined as any glycan that is not in groups 1 or 2, does not contain any fucose residues,
but contains sialic acid); 4) complex or hybrid type structures containing sialic acid and
fucose residues (defined as any glycan that is not in groups 1 or 2, and contains both sialic
acid and fucose residues); 5) complex or hybrid type structures that contain fucose and
multiple terminal HexNAc residues; (defined as any glycan that is not in groups 1-4, does
not contain sialic acid, and has at least one fucose residue and a greater number of HexNAc
than Hex residues); 6) complex/hybrid type structures that contain fucose and terminal Hex
residues (defined as any glycan that is not in groups 1-5, does not contain sialic acid, has at
least one fucose residue, and has a greater number of Hex than HexNAc residues); 7)
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complex/hybrid type structures with multiple terminal HexNAc residues but no sialic acid or
fucose; (which is the same as group 5 glycans, except no fucose is present); and 8) complex/
hybrid type structures that lack sialic acid or fucose and contain terminal Hex residues
(which is the same as group 6 glycans, except no fucose is present). The glycan
classification system described above was developed to account for the fact that
glycopeptides with these different glycan components fragment differently and have
different diagnostic ions identifying them. This approach is also supported by recently
published research that shows the types of product ions in tandem mass spectra of
glycopeptides vary, depending on the unique glycan substituents present. 33 The diagnostic
ions that are scored for each glycan type are depicted in Figure 2.
In addition to determining which diagnostic ions should be scored for each of the candidate
glycopeptide compositions, we also implemented noise-reduction and intensity-based
scoring components into the algorithm. A baseline noise correction is applied before the
automatic “spectral match searching” is performed in order to limit false positive peak
matches arising from noise. In preliminary testing, a cut-off of 2% has been found to be
ideal for most spectra, but the algorithm allows the user to vary this cut-off, so that spectra
of differing quality (noise levels) can be scored using different thresholds for noise
reduction.
In addition, the relative abundance of the [precursor – monosaccharide] product ions is taken
into account when determining whether or not a peak corresponding to a particular m/z is
actually from the neutral loss being evaluated, with varying threshold limits being applied
according to the composition of the monosaccharide resides in the neutral loss being scored.
For example, as fucose and sialic acid are more labile than Hex or HexNAc residues, the
threshold applied to the detection of product ions resulting from cleavage of these residues is
much higher than the threshold applied to the scoring of product ions that arise from the
cleavage of Hex and HexNAc residues. This feature was implemented to reduce the
possibility of false positive matches. Detailed information on the normalization thresholds
used in the scoring scheme can be found in the complete algorithm, supplied in
Supplementary Materials.
Candidate Composition Scoring by GPG
After algorithm development, MS/MS data of glycopeptide spectra from RNase B,
asialofetuin, and transferrin were scored using the GPG software. The resultant collection of
CID spectra is referred to herein as the training data set. For each case, the known
composition of the glycopeptide was scored against at least three decoy compositions, which
were generated as described in the experimental section. Glycopeptide data from a variety of
precursor charge states were scored.
In Figure 3, an example of the candidate composition scoring by GPG is shown for a CID
spectrum collected from a high mannose type glycopeptide from RNase B. The same
spectrum is shown in Figures 3A, B, and C. However, each panel shows a different
candidate composition for this spectrum and includes the results of how GPG scored each
composition. The correct composition is in 3A, while two decoy compositions are shown in
Figures 3B and 3C. The [precursor – monosaccharide] product ions searched by GPG are
calculated based on the candidate composition. For candidate A, which contains a high
mannose glycan, GPG predicts the sequential loss of mannose residues from the precursor
ion and evaluates the [precursor – monosaccharide] product ions by searching the MS2 peak
list for the m/z values corresponding to sequential losses of individual hexose residues.
Candidate compositions B and C are both classified as complex or hybrid glycans without
sialic acid or fucose, so the same set of fragmentation rules applies for the glycan
component in these two spectra. In addition to variations in the glycan scoring, each
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spectrum is scored differently for the [peptide + core component] ions, because each
spectrum has a different candidate peptide composition. As a result, GPG returns separate
scores for the candidate compositions in B and C, even though the glycan portions are
similar. The calculations for the different types of fragmentation ions are weighted by the
software, with [peptide + core component] product ions accounting for 67% and [precursor
– monosaccharide] product ions accounting for 33% of the score. GPG reports a final score
of 97% for the correct glycopeptide assignment (candidate composition A), 20% for the first
decoy glycopeptide assignment (candidate composition B) and 27% for the second decoy
glycopeptide assignment (candidate composition C).
A second example of spectra scored by GPG is presented in Supplementary Figure 1. In this
case, different types of [precursor – monosaccharide] product ions are searched, as different
glycans are present in the candidate and decoy compositions. The CID spectrum for
Supplemental Figure 1 is a sialylated glycopeptide from transferrin. Associated text in the
Supplemental section also describes how GPG scores these spectra.
In Supplemental Table 2, 45 test examples are provided that show GPG scores for
glycopeptides analyzed from experimental MS/MS data in the training data set. In each
example, the correct composition is compared against at least 2 decoy compositions of the
same nominal mass. A wide variety of glycopeptide compositional arrangements were
tested. Over 150 glycopeptide spectra from the 45 unique glycopeptides in the training data
set were scored using GPG, with the correct candidate receiving the highest score in each
test performed.
GPG Validation: Application to Recombinant Gp120 HIV Envelope Glycoprotein
As the GPG algorithm was designed after studying the fragmentation patterns obtained for
RNase B, asialofetuin, and transferrin, whose spectra comprise the training data set, it was
expected that the automated GPG tool would perform well when testing the training data set.
Therefore, after analysis of the training data set, the GlycoPep Grader software was used to
analyze CID data collected on tryptic digests of the HIV envelope protein, CON-S gp140
CFI. The resulting CID spectra from the CON-S gp 140 CFI glycopeptides (herein referred
to as the validation data set) contains MS/MS data on glycopeptides of varying N-linked
glycan types and compositional arrangements. A total of over 100 CID spectra from 34
unique CON-S gp140 CFI glycopeptides were tested using the GPG tool. The results are
summarized in Supplemental Table 3. A minimum of 3 candidate compositions were scored
for each spectrum, with an average of 4-5 glycopeptide candidates being evaluated in each
test performed. In agreement with the training data set results, the GPG algorithm assigned
the highest score to each correct candidate composition, for each CON-S gp140 CFI
glycopeptide spectrum, scored in the validation data set. An example of a scored fucosylated
complex-type structure from CON-S gp140 CFI is shown in Figure 4. The GPG scores for
decoy compositions tested against this spectrum are also reported on the spectra. This
example is Test 31 of Supplementary Table 3.
While the data from both the training sets and validation sets were quite encouraging, one
might note that in each case, a limited number of decoys were tested against the true
composition. To test the likelihood that this limited number of decoys was a required feature
for the correct candidate to get the top score, a glycopeptide spectrum from gp140 was
tested against 9 alternate isobaric candidate compositions. Scores are shown in Table 1, and
the MS/MS data is in Supplemental Figure 2. The correct composition of NCSFNITTEIR +
[HexNAc]4[Hex]4[Fuc]1 was indicated with the highest GPG score, 80%, while the highest
scoring decoy composition, INETLELLSESPVYSTK + [HexNAc]2[Hex]3[Fuc]1 was
assigned a GPG score of 68%. Although the score values and distribution varies from
spectrum to spectrum, GPG ranked the correct candidate composition as the most probable
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glycopeptide in each test performed, including approximately 300 CID spectra from the
training and validation sets. A screen shot of the GPG scoring output for a high mannose
type CON-S gp140 CFI glycopeptide, along with three decoy candidate compositions, is
included in Supplemental Figure 3.
CONCLUSION
We have developed a novel software analysis tool, GlycoPep Grader, to increase the speed
and efficiency of assigning N-linked glycopeptide composition from MS/MS data. This
novel spectral scoring approach relies heavily on the identification of the peptide-containing,
or [peptide + core component], product ions and neutral monosaccharide residue losses, or
[precursor – monosaccharide] product ions, across various charge states. After developing
and testing the GPG software using a training set of CID data collected on glycopeptides
from RNase B, asialofetuin, and transferrin, GPG was then validated by scoring
glycopeptide compositions from the recombinant HIV envelope protein, CON-S gp140 CFI,
against alternate candidate compositions of the same nominal mass. Thus far, in the
approximately 300 tests performed across spectra of differing quality, the novel scoring
algorithm powering GPG identifies the correct glycopeptide composition as the highest
scoring candidate ion every time.
This tool has several useful features, compared to other existing glycopeptide analysis tools.
It is the only available tool whose scoring algorithm was designed specifically for low-
resolution CID data. It does not require the user to first deconvolute the spectrum to singly
charged ions, which is often difficult or impossible for low-resolution CID spectra. The user
need not know the peptide composition in advance in order to use the tool, but rather inputs
potential candidate compositions obtained from available glycopeptide databases that
correspond to the precucursor’s experimental mass. It has unique scoring rules, depending
on the types of glycans present in the candidate composition. Finally, it has shown
unprecedented success in accurately identifying of the correct glycopeptide composition in
79 unique test cases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CID data from model N-linked glycopeptides used to generate GPG algorithm fragmentation
rules. A high mannose glycopeptide from RNAse B is shown in A.; a sialylated complex
glycopeptide from transferrin is shown in B.; and a complex glycopeptide from asialofetuin
is shown in C. The spectra at left in A. – C. show the peptide-containing, or [peptide + core
component], product ions detectable for all N-linked glycopeptides (regardless of the glycan
attached), while spectra at the right in A. – C. show those product ions that result from
neutral losses of monosaccharides, [precursor – monosaccharide], found to be unique to
each N-glycan type. (Diagnostic neutral losses analyzed by GPG are shown in color, while
other neutral losses that are not useful in determining the glycan type are shown in gray.)
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Diagram of ions scored by GlycoPep Grader (GPG) algorithm for (A) [peptide + core
component] and (B) [precursor – monosaccharide] product ions expected for each of the
eight group types, described in the text. In (A), the six different [peptide + core component]
product ions that are searched by GPG are depicted. In (B), the monosaccharide neutral
losses evaluated for group 1 (see manuscript text) are shown in the purple oval; for group 2,
the relevant losses are shown in both the purple oval and the yellow circle; group 3, the
relevant losses are shown in the blue oval; group 4, in the blue oval and yellow circle; group
5, in the yellow oval and yellow circle; group 6, in the green oval and yellow circle; group 7
and group 8, neutral losses are in the yellow oval at bottom left, and by the green oval at
bottom right, respectively.
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CID data of an RNAse B glycopeptide from the training data. A) GPG scoring of the correct
glycopeptide composition (97%) B) and C) Scoring of two decoy compositions of the same
nominal mass (Scores are 20% and 27% respectively). Exact neutral masses of candidate
compositions (A), (B), and (C) are, in order: 2419.9945, 2419.9733, and 2419.9978. The X’s
on the spectra indicate the absence of a product ion that was predicted to be present by GPG
for a given candidate composition. A 2% relative abundance threshold was used for [peptide
+ core component] product ion matching to decrease false positives from noise.
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MS2 data from the validation set. (A) GPG evaluation of the correct candidate composition
assignment for a fucosylated N-glycopeptide from CON-S gp140ΔCFI. Scoring in (B) and
(C) shows evaluation of this spectrum against decoy candidate compositions with the same
nominal mass. Arrows with X’s indicate ions that were not present in the spectra. A 2%
relative abundance threshold was used for [peptide + core component] product ion matching
to decrease false positives from noise. For the composition in A, GPG generated a score of
95%. The decoy compositions in B) and C) were scored at 52% and 68% respectively,
indicating that GPG scored the correct compositional assignment as the most probable
composition from this pool of candidates.
Woodin et al. Page 14

























Woodin et al. Page 15
Table 1
GPG score results for 10 candidate compositions tested against the MS2 data shown in Supplementary Figure
2.
Mass Glycopeptide Candidate A Composition B Score C
2960.2338 1. NCSFNITTEIR + [HexNAc]4[Hex]4[Fuc]1 80
2960.3006 2. YILKLENSSGSK + [HexNAc]4 + [Hex]5 52
2960.3228 3. QNATVQGLIQGK + [HexNAc]6[Hex]3 39
2960.2638 4. YTVVAGGNVSTAK + [HexNAc]3[Hex]4[Neu5Ac]1[Fuc]1 11
2960.2740 5. NGTEILKSK + [HexNAc]5[Hex]5[Fuc]1 32
2960.2700 6. VENLTEGAIYYFR + [HexNAc]3[Hex]3[Neu5Ac]1 0
2960.2644 7. YTLTLENSSGTK + [HexNAc]5[Hex]3[Fuc]1 34
2960.2642 8. YILTVENSSGSK + [HexNAc]5[Hex]4 44
2960.2484 9. TKANVTVEAR + [HexNAc]3[Hex]6[Neu5Ac]1 0
2960.3632 10. INETLELLSESPVYSTK + [HexNAc]2[Hex]3[Fuc]1 68
A
Candidate 1 is the actual glycopeptide corresponding to the MS/MS data analyzed by GPG and candidates 2-10 are decoy compositions of nearly
identical neutral mass.
B
All candidate compositions have an in silico m/z that is within 50 ppm error of the monoisotopic mass present in the experimental MS1 data.
Users may also utilize low resolution MS1 data to determine glycopeptide candidates, though more compositions will result.
C
Denotes GPG scores at 2% peptide normalization.
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